Clinical trial
Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for…
NCT00135200 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00135200 |
|---|---|
| Title | Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma |
| Official title | A Phase II Clinical Trial of Consolidation Treatment With Iodine I 131 Tositumomab for Multiple Myeloma |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Collaborators | GlaxoSmithKline Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Iodine I 131 Tositumomab |
| Enrollment | 16 |
| Start date | Aug 1, 2005 |
| Primary completion | Aug 1, 2013 |
| Completion | Sep 4, 2024 |
| First posted | Aug 25, 2005 |
| Last update posted | Apr 30, 2025 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: